After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower prostate cancer mortality with PSA testing and an improved harm–benefit ratio over time. Risk-based screening could sustain mortality gains while reducing overdiagnosis and unnecessary treatment.